GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » 5-Year Yield-on-Cost %
中文

Novavax (Novavax) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Novavax 5-Year Yield-on-Cost %?

Novavax's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Novavax's 5-Year Yield-on-Cost % or its related term are showing as below:



NVAX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 2.005
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Novavax's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Novavax's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Novavax's 5-Year Yield-on-Cost % falls into.



Novavax 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Novavax is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Novavax  (NAS:NVAX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Novavax 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Novavax's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100